Global R&D Pipeline
My Favorite
Hot Targets:
GLP-1R
Back
Total number of drugs
699
Phase II and later clinical stages
17%
Involving companies
674
Main therapeutic areas
Endocrinology and Metabolic Disease
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tirzepatide(Geropharm LLC) | Tirzepatide(Geropharm LLC) | Synthetic peptide | Endocrinology and Metabolic Disease | GIPR agonists GLP-1R agonists | Geropharm LLC | Geropharm LLC | Approved | - | Russia | 2025-04-17 | - | - | - | - | - | - | Tirzepatide(Geropharm LLC) | - | - | detail > | |
| Mazdutide | Mazdutide | Synthetic peptide | Endocrinology and Metabolic Disease Digestive System Disorders Cardiovascular Diseases Urogenital Diseases Nervous System Diseases Respiratory Diseases Other Diseases Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | GCGR agonists GLP-1R agonists | Eli Lilly & Co. | Eli Lilly & Co. Innovent Biologics (Suzhou) Co. Ltd. Innovent Biologics (HK) Ltd. | Approved | Approved | China | 2025-06-24 | 2025-06-24 | - | - | - | - | - | Mazdutide | - | - | detail > | |
| Insulin Glargine/Lixisenatide | Insulin Glargine/Lixisenatide | Hormone | Endocrinology and Metabolic Disease | GLP-1R agonists INSR agonists | Sanofi | Sanofi-Aventis Canada, Inc. Sanofi Winthrop Industrie SA Sanofi KK Sanofi-Aventis U.S. LLC Sanofi | Approved | Approved | United States China European Union Japan Canada Switzerland Iceland Liechtenstein Norway | 2002-05-16 | 2023-01-10 | Priority Review（China） | - | - | - | - | Insulin Glargine/Lixisenatide | - | - | detail > | |
| Exenatide | Exenatide | Synthetic peptide | Endocrinology and Metabolic Disease Nervous System Diseases | GLP-1R agonists | Eli Lilly & Co. Amylin Pharmaceuticals, Inc. | University College London Amylin Pharmaceuticals, Inc. Eli Lilly Nederland BV ICURE PHARM INC AstraZeneca AB AstraZeneca KK | Approved | Approved | United States China European Union Japan Iceland Liechtenstein Norway | 2005-04-28 | 2009-05-08 | Orphan Drug（European Union） | - | - | - | - | Exenatide | - | - | detail > | |
| Liraglutide | Liraglutide | Recombinant polypeptide | Endocrinology and Metabolic Disease Nervous System Diseases Other Diseases | GLP-1R agonists | Novo Nordisk A/S | Novo Nordisk A/S Izmir Ekonomi Üniversitesi Novo Nordisk, Inc. Nanexa AB Università degli Studi di Napoli Federico II Novo Nordisk Pharmaceuticals Pty Ltd. | Approved | Approved | United States China European Union Japan Canada Australia Iceland Liechtenstein Norway | 2009-06-30 | 2011-03-04 | - | - | - | - | - | Liraglutide | - | - | detail > | |
| Lixisenatide | Lixisenatide | Synthetic peptide | Endocrinology and Metabolic Disease | GLP-1R agonists | Zealand Pharma A/S | Sanofi Winthrop Industrie SA Sanofi-Aventis Canada, Inc. Sanofi KK Sanofi-Aventis U.S. LLC | Approved | Withdrawn | United States European Union Japan Canada Iceland Liechtenstein Norway | 2013-01-31 | 2019-02-23 | - | - | - | - | - | Lixisenatide | - | - | detail > | |
| Dulaglutide | Dulaglutide | Fc fusion protein | Endocrinology and Metabolic Disease | GLP-1R agonists | Eli Lilly & Co. | Eli Lilly Nederland BV Eli Lilly & Co. Eli Lilly Australia Pty Ltd. | Approved | Approved | United States China European Union Japan Australia Iceland Liechtenstein Norway | 2014-09-18 | 2019-02-22 | Priority Review（China） | - | - | - | - | Dulaglutide | - | - | detail > | |
| Insulin Degludec / Liraglutide | Insulin Degludec / Liraglutide | Hormone | Endocrinology and Metabolic Disease | GLP-1R agonists INSR agonists | Novo Nordisk A/S | Novo Nordisk A/S Novo Nordisk, Inc. Novo Nordisk Canada, Inc. | Approved | Approved | United States China European Union Japan Canada Iceland Liechtenstein Norway | 2014-09-18 | 2022-03-08 | - | - | - | - | - | Insulin Degludec / Liraglutide | - | - | detail > | |
| Beinaglutide | Beinaglutide | Recombinant polypeptide | Endocrinology and Metabolic Disease | GLP-1R agonists | Shanghai Benemae Pharmaceutical Corp. | Shanghai Benemae Pharmaceutical Corp. | Approved | Approved | China | 2016-12-13 | 2016-12-13 | - | - | - | - | - | Beinaglutide | - | - | detail > | |
| Liraglutide(Meitheal Pharmaceuticals) | Liraglutide(Meitheal Pharmaceuticals) | Synthetic peptide | Endocrinology and Metabolic Disease | GLP-1R agonists | Meitheal Pharmaceuticals, Inc. | Meitheal Pharmaceuticals, Inc. | Approved | - | United States | 2025-04-03 | - | - | - | - | - | - | Liraglutide(Meitheal Pharmaceuticals) | - | - | detail > |
Total 699 data
1
2
3
4
5
6
...
69
70
